Abiopharma

SEPTERNA, INC. (SEPN)

Symbol	SEPN
Name	SEPTERNA, INC.
Sector	HEALTH CARE
Region	North America
Industry	Biotechnology: Pharmaceutical Preparations
Address	250 EAST,GRAND AVENUE, SOUTH SAN FRANCISCO, California, 94080, United States
Telephone	650-338-3533
Fax	—
Email	—
Website	https://septerna.com
Incorporation	UNDEFINED
Incorporated On	—
Employees	—
Fiscal Year	—
Public Since	—
Exchanges	NASDAQ
Auditor	—
Audit Status	NOT PROVIDED
Reporting Status	—
CIK	0001984086
Description	Septerna is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by its proprietary Native Complex Platform. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Our lead product candidate, SEP-786, is a clinical-stage, oral small molecule agonist targeting PTH1R for the treatment of hypoparathyroidism. We have successfully completed Investigational New Drug (IND)-enabling studies and have initiated a Phase 1 clinical trial to assess preliminary safety, tolerability, PK, and PD of SEP-786. Additional info from NASDAQ: Septerna is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by its proprietary Native Complex Platform. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Our lead product candidate, SEP-786, is a clinical-stage, oral small molecule agonist targeting PTH1R for the treatment of hypoparathyroidism. We have successfully completed Investigational New Drug (IND)-enabling studies and have initiated a Phase 1 clinical trial to assess preliminary safety, tolerability, PK, and PD of SEP-786.

2026-08-14 21:44

Third Rock Ventures V, L.P. 🟢 acquired 147.2K shares of Septerna, Inc. (SEPN) at $51.08 ($7.4M) Transaction Date: Aug 12, 2026 | Filing ID: 352692

2026-08-14 21:11

RA CAPITAL MANAGEMENT, L.P. 🔴 sold 1.5M shares of Septerna, Inc. (SEPN) at $42.50 ($63.5M) Transaction Date: Aug 12, 2026 | Filing ID: 000938

2026-08-14 18:14

New Form SCHEDULE 13D/A - Septerna, Inc. Filed: 2026-08-14 AccNo: 0001346824-26-000228 Size: 16 KB

2026-08-14 08:32

New Form SCHEDULE 13G/A - Septerna, Inc. Filed: 2026-08-14 AccNo: 0000938206-26-000037 Size: 7 KB

2026-08-13 23:00

Bhatt Elizabeth 🟡 adjusted position in 25.0K shares (2 derivative) of Septerna, Inc. (SEPN) at $44.00 ($1.4M) Transaction Date: Aug 11, 2026 | Filing ID: 349810

2026-08-12 23:06

📋 RA Capital Healthcare Fund LP (affiliate) plans to sell 746K shares of Septerna, Inc. (at $48.19 each, total $36.0M) Filed: Aug 12, 2026 | ID: 000042

2026-08-12 22:55

📋 RA Capital Nexus Fund III, L.P. (Affiliate) plans to sell 746K shares of Septerna, Inc. (at $48.19 each, total $36.0M) Filed: Aug 12, 2026 | ID: 000041

2026-08-12 20:09

📋 Third Rock Ventures V, L.P. (10% Stockholder) plans to sell 147K shares of Septerna, Inc. (at $51.00 each, total $7.5M) Filed: Aug 12, 2026 | ID: 000301

2026-08-11 20:28

📋 ELIZABETH P. BHATT (Officer) plans to sell 29K shares of Septerna, Inc. (at $38.85 each, total $1.1M) Filed: Aug 11, 2026 | ID: 007956

2026-08-10 20:03

(30% Negative) SEPTERNA, INC. (SEPN) Reports Q3 2026 Financial Results

Trial ID	Title	Phase	Indication	Status	Start Date	Completion Date	Source
NCT07433179	A Study to Evaluate Single and Multiple Doses of SEP-479 in Healthy Adult Parti…	Phase1	Healthy Volunteers	Recruiting	2026-03-04	2027-02-01	ClinicalTrials.gov
NCT07069036	A Study to Evaluate Single and Multiple Doses of SEP-631 in Healthy Adult Volun…	Phase1	Healthy Volunteers	Completed	2025-07-15	2025-12-18	ClinicalTrials.gov

Total clinical trials: 2

Product Name	Type	Development Stage	Therapeutic Area	Study Status	Trial ID
Placebo	Other	Phase PHASE1	Healthy Volunteers	RECRUITING	NCT07433179
SEP-479	Other	Phase PHASE1	Healthy Volunteers	RECRUITING	NCT07433179
Placebo	Other	Phase PHASE1	Healthy Volunteers	RECRUITING	NCT07433179
SEP-479	Other	Phase PHASE1	Healthy Volunteers	RECRUITING	NCT07433179
Placebo	Other	Phase PHASE1	Healthy Volunteers	RECRUITING	NCT07433179
SEP-479	Other	Phase PHASE1	Healthy Volunteers	RECRUITING	NCT07433179
Placebo	Other	Phase PHASE1	Healthy Volunteers	RECRUITING	NCT07433179
SEP-479	Other	Phase PHASE1	Healthy Volunteers	RECRUITING	NCT07433179
Placebo	Other	Phase PHASE1	Healthy Volunteers	RECRUITING	NCT07433179
SEP-479	Other	Phase PHASE1	Healthy Volunteers	RECRUITING	NCT07433179
Placebo	Other	Phase PHASE1	Healthy Volunteers	RECRUITING	NCT07433179
SEP-479	Other	Phase PHASE1	Healthy Volunteers	RECRUITING	NCT07433179
Placebo	Other	Phase PHASE1	Healthy Volunteers	COMPLETED	NCT07069036
SEP-631	Other	Phase PHASE1	Healthy Volunteers	COMPLETED	NCT07069036
Placebo	Other	Phase PHASE1	Healthy Volunteers	RECRUITING	NCT07433179
SEP-479	Other	Phase PHASE1	Healthy Volunteers	RECRUITING	NCT07433179
Placebo	Other	Phase PHASE1	Healthy Volunteers	COMPLETED	NCT07069036
SEP-631	Other	Phase PHASE1	Healthy Volunteers	COMPLETED	NCT07069036
Placebo	Other	Phase PHASE1	Healthy Volunteers	RECRUITING	NCT07433179
SEP-479	Other	Phase PHASE1	Healthy Volunteers	RECRUITING	NCT07433179
Placebo	Other	Phase PHASE1	Healthy Volunteers	COMPLETED	NCT07069036
SEP-631	Other	Phase PHASE1	Healthy Volunteers	COMPLETED	NCT07069036
Placebo	Other	Phase PHASE1	Healthy Volunteers	COMPLETED	NCT07069036
SEP-631	Other	Phase PHASE1	Healthy Volunteers	COMPLETED	NCT07069036
Placebo	Other	Phase PHASE1	Healthy Volunteers	COMPLETED	NCT07069036
SEP-631	Other	Phase PHASE1	Healthy Volunteers	COMPLETED	NCT07069036
Placebo	Other	Phase PHASE1	Healthy Volunteers	COMPLETED	NCT07069036
SEP-631	Other	Phase PHASE1	Healthy Volunteers	COMPLETED	NCT07069036
Placebo	Other	Phase PHASE1	Healthy Volunteers	COMPLETED	NCT07069036
SEP-631	Other	Phase PHASE1	Healthy Volunteers	COMPLETED	NCT07069036
Placebo	Other	Phase PHASE1	Healthy Volunteers	COMPLETED	NCT07069036
SEP-631	Other	Phase PHASE1	Healthy Volunteers	COMPLETED	NCT07069036

Total products: 32